Zacks Investment Research downgraded shares of Senseonics Holdings Inc (NASDAQ:SENS) from a hold rating to a sell rating in a report published on Wednesday.
According to Zacks, “Senseonics Holdings, Inc. is a medical technology company which focused on the design, development and commercialization of glucose monitoring systems. Senseonics Holdings, Inc. is based in Germantown, United States. “
SENS has been the subject of several other research reports. B. Riley restated a buy rating and issued a $4.00 target price on shares of Senseonics Holdings in a research report on Wednesday, May 10th. BTIG Research restated a buy rating and issued a $4.50 target price on shares of Senseonics Holdings in a research report on Sunday, May 28th.
Senseonics Holdings (SENS) opened at 2.49 on Wednesday. Senseonics Holdings has a 1-year low of $1.26 and a 1-year high of $4.10. The firm’s market capitalization is $306.77 million. The firm’s 50-day moving average price is $2.17 and its 200-day moving average price is $1.98.
Senseonics Holdings (NASDAQ:SENS) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. The business had revenue of $0.81 million for the quarter, compared to the consensus estimate of $0.81 million. On average, equities research analysts predict that Senseonics Holdings will post ($0.54) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This piece of content was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2017/08/13/senseonics-holdings-inc-sens-stock-rating-lowered-by-zacks-investment-research.html.
In other news, major shareholder Enterprise Associates 10 L. New bought 7,092,198 shares of the firm’s stock in a transaction on Thursday, June 1st. The stock was purchased at an average price of $1.41 per share, for a total transaction of $9,999,999.18. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink.
A number of hedge funds and other institutional investors have recently bought and sold shares of SENS. Renaissance Technologies LLC purchased a new position in Senseonics Holdings during the first quarter valued at approximately $111,000. Raymond James Financial Services Advisors Inc. purchased a new position in Senseonics Holdings during the first quarter valued at approximately $147,000. LMR Partners LLP purchased a new position in Senseonics Holdings during the second quarter valued at approximately $177,000. ING Groep NV boosted its position in Senseonics Holdings by 87.7% in the second quarter. ING Groep NV now owns 225,833 shares of the company’s stock valued at $406,000 after buying an additional 105,494 shares during the period. Finally, HarbourVest Partners LLC purchased a new position in Senseonics Holdings during the first quarter valued at approximately $470,000.
Senseonics Holdings Company Profile
Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Senseonics Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.